STA
CLVS

Summit Trail Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Summit Trail Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-6,721
Closed -$249K – 703
2018
Q1 		$249K Buy
6,721
+776
+13% +$45.3K 0.04% 320
2017
Q4 		$369K Buy
+5,945
New +$416K 0.05% 277

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Summit Trail Advisors's CLVS Position: Q2 2018 in Review

Summit Trail Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q2 2018, closing a stake of 6,721 shares — an estimated $249K sold.

Summit Trail Advisors first reported a position in CLVS in Q4 2017 and held it in 2 quarters. The position peaked at $369K in Q4 2017. 210 funds tracked by Wall St. Rank hold CLVS as of Q2 2018.

  • Summit Trail Advisors reported no remaining Clovis Oncology, Inc. position as of Q2 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 6,721 Clovis Oncology, Inc. shares in Q2 2018, an estimated $249K.
  • Summit Trail Advisors first reported a position in Clovis Oncology, Inc. in Q4 2017 and held it in 2 quarters.
  • Summit Trail Advisors's Clovis Oncology, Inc. position peaked at $369K in Q4 2017.
  • 210 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2018.

Based on Summit Trail Advisors's 13F filing for Q2 2018, filed 10 Aug 2018.